Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis

Leukemia

Volumn 22, Issue 9, 2008, Pages 1806-1807

  Khorashad, J S ^a   De Melo, V A ^a   Fiegler, H ^b   Gerrard, G ^a   Marin, D ^a   Apperley, J F ^a   Goldman, J M ^a   Foroni, L ^a   Reid, A G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Roche Diagnostics UK Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MIXED LINEAGE LEUKEMIA PROTEIN; NOTCH RECEPTOR;

ALU SEQUENCE; ARTICLE; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA EXTRACTION; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE AMPLIFICATION; GENE DELETION; GENE DUPLICATION; GENETIC DAMAGE; GENETIC SCREENING; GENOME; HOMOLOGOUS RECOMBINATION; HUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURAL CHROMOSOME ABERRATION;

CYTOGENETIC ANALYSIS; GENOMIC INSTABILITY; GENOMICS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

EID: 51649102491     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.210     Document Type: Article

References (11)

1. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441-453.
2. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
3. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
4. Brazma D, Grace C, Howard J, Melo JV, Holyoke T, Apperley JF, Nacheva EP. Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes Cancer 2007; 46: 1039-1050.
5. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114.
6. Jia SH, Li Y, Parodo, J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-1327.
7. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A et al Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6: 363-375.
8. Kendal CE, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor (PBEF/ Visfatin) gene expression is modulated by NF-kappaB and AP-1 in human amniotic epithelial cells. Placenta 2007; 28: 305-314.
9. Liu YX, Wang J, Guo J, Wu J, Lieberman HB, Yin Y. DUSP1 is controlled by p53 during the cellular response to oxidative stress. Mol Cancer Res 2008; 6: 624-633.
10. Lupski JR, Stankiewicz P. Genomic disorders: Molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet 2005; 1: e49.
11. Saglio G, Storlazzi CT, Giugliano E, Surace C, Anelli L, Rege-Cambrin G et al. A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: Possible involvement in the genesis of the Philadelphia chromosome translocation. Proc Natl Acad Sci USA 2002; 99: 9882-9887.